Examining the Utility of Patient-derived Xenograft Mouse Models

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2015 Apr 25

PMID 25907221

Citations 198

Authors

Samuel Aparicio

Manuel Hidalgo

Andrew L Kung

Affiliations

Soon will be listed here.

Abstract

Patient-derived xenograft (PDX) models are now being widely used in cancer research and have the potential to greatly inform our understanding of cancer biology. However, many questions remain, especially regarding the ability of PDX models to affect clinical decision making. With these points in mind, we asked three scientists to give their opinions on the generation and uses of PDX models and the future of this field.

Citing Articles

Novel organoid model in drug screening: Past, present, and future.

Nie X, Liang Z, Li K, Yu H, Huang Y, Ye L Liver Res. 2025; 5(2):72-78.

PMID: 39959346 PMC: 11791835. DOI: 10.1016/j.livres.2021.05.003.

Functional biomaterials for biomimetic 3D in vitro tumor microenvironment modeling.

Ahmed T In Vitro Model. 2025; 2(1-2):1-23.

PMID: 39872875 PMC: 11756483. DOI: 10.1007/s44164-023-00043-2.

Establishment of Biobank and Patient-Derived Xenograft of Soft Tissue and Bone Tumors.

Okada S, Boonnate P, Panaampon J, Saisuwan K, Ogata-Aoki H, Abe M Cureus. 2024; 16(11):e74781.

PMID: 39737254 PMC: 11684544. DOI: 10.7759/cureus.74781.

From Cancer to Immune Organoids: Innovative Preclinical Models to Dissect the Crosstalk between Cancer Cells and the Tumor Microenvironment.

Picca F, Giannotta C, Tao J, Giordanengo L, Munir H, Botta V Int J Mol Sci. 2024; 25(19).

PMID: 39409152 PMC: 11476904. DOI: 10.3390/ijms251910823.

Thermo-Responsive Hydrogel Based on Lung Decellularized Extracellular Matrix for 3D Culture Model to Enhance Cancer Stem Cell Characteristics.

Chen L, Li F, Li R, Zheng K, Zhang X, Ma H Molecules. 2024; 29(18).

PMID: 39339380 PMC: 11433703. DOI: 10.3390/molecules29184385.

References

Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H . Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2014; 518(7539):422-6. PMC: 4864027. DOI: 10.1038/nature13952. View

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A . Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008; 14(20):6456-68. DOI: 10.1158/1078-0432.CCR-08-0138. View

Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas P, Megias D, Guerra C . Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013; 109(4):926-33. PMC: 3749580. DOI: 10.1038/bjc.2013.415. View

Kalscheuer H, Danzl N, Onoe T, Faust T, Winchester R, Goland R . A model for personalized in vivo analysis of human immune responsiveness. Sci Transl Med. 2012; 4(125):125ra30. PMC: 3697150. DOI: 10.1126/scitranslmed.3003481. View

Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S . Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas. 2004; 29(3):193-203. DOI: 10.1097/00006676-200410000-00004. View

Lock R, Liem N, Papa R . Preclinical testing of antileukemic drugs using an in vivo model of systemic disease. Methods Mol Med. 2005; 111:323-34. DOI: 10.1385/1-59259-889-7:323. View

Zhang X, Claerhout S, Prat A, Dobrolecki L, Petrovic I, Lai Q . A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013; 73(15):4885-97. PMC: 3732575. DOI: 10.1158/0008-5472.CAN-12-4081. View

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P . A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007; 13(13):3989-98. DOI: 10.1158/1078-0432.CCR-07-0078. View

Morelli M, Calvo E, Ordonez E, Wick M, Viqueira B, Lopez-Casas P . Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol. 2011; 30(4):e45-8. PMC: 4874230. DOI: 10.1200/JCO.2011.36.9678. View

10.

Martinez-Garcia R, Juan D, Rausell A, Munoz M, Banos N, Menendez C . Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med. 2014; 6(4):27. PMC: 4062047. DOI: 10.1186/gm544. View

11.

Garrido-Laguna I, Uson M, Rajeshkumar N, Tan A, de Oliveira E, Karikari C . Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011; 17(17):5793-800. PMC: 3210576. DOI: 10.1158/1078-0432.CCR-11-0341. View

12.

Peterson J, Houghton P . Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer. 2004; 40(6):837-44. DOI: 10.1016/j.ejca.2004.01.003. View

13.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J . Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat. 2012; 135(2):415-32. PMC: 3818141. DOI: 10.1007/s10549-012-2164-8. View

14.

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

15.

Ding L, Ellis M, Li S, Larson D, Chen K, Wallis J . Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010; 464(7291):999-1005. PMC: 2872544. DOI: 10.1038/nature08989. View

16.

Hidalgo M, Amant F, Biankin A, Budinska E, Byrne A, Caldas C . Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014; 4(9):998-1013. PMC: 4167608. DOI: 10.1158/2159-8290.CD-14-0001. View

17.

Johnson J, Decker S, Zaharevitz D, Rubinstein L, Venditti J, SCHEPARTZ S . Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001; 84(10):1424-31. PMC: 2363645. DOI: 10.1054/bjoc.2001.1796. View

18.

Boven E, Winograd B, Berger D, Dumont M, Braakhuis B, Fodstad O . Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res. 1992; 52(21):5940-7. View

19.

Vidal A, Munoz C, Guillen M, Moreto J, Puertas S, Martinez-Iniesta M . Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res. 2012; 18(19):5399-411. DOI: 10.1158/1078-0432.CCR-12-1513. View

20.

Li X, Nadauld L, Ootani A, Corney D, Pai R, Gevaert O . Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med. 2014; 20(7):769-77. PMC: 4087144. DOI: 10.1038/nm.3585. View